Insights from 2024 WCLC


 

WCLC 2024 Insights: LAURA Study - Osimertinib After Definitive CRT in Unresectable Stage III EGFRm NSCLC

90 views
September 18, 2024
0 Comments
Login to view comments. Click here to Login